| To: | Glaxo Group Limited (trademarks@gsk.com) |
| Subject: | TRADEMARK APPLICATION NO. 88381582 - NAMVONA - 82774078 |
| Sent: | 12/4/2019 6:15:56 AM |
| Sent As: | ECOMPET |
| Attachments: |
United States Patent and Trademark Office (USPTO)
|
U.S. Application Serial No. 88381582
Mark: NAMVONA
|
|
|
Correspondence Address: Merilee J. Arevalo GSK LBP, 5.5A 5 MOORE DRIVE RESEARCH TRIANGLE PARK NC 27709-3398 |
|
|
Owner: Glaxo Group Limited
|
|
|
Reference/Docket No. 82774078
Correspondence Email Address: trademarks@gsk.com |
|
PETITION TO DIRECTOR INQUIRY LETTER
The USPTO must receive petitioner’s response to this letter within 30 days of the issue date below. Respond using the Trademark Electronic System (TEAS). A link to the appropriate TEAS response form appears at the end of this letter.
Issue date: December 4, 2019
Your post publication request to substitute or add a filing basis for the above identified trademark application was received on October 1, 2019. After publication, a petition to the Director is required to change the basis of an application. Trademark Rule 2.35(b)(2). Therefore, you must submit the $100 petition fee.
You must submit the $100 petition fee no later than thirty (30) days from the mailing date of this letter. If a timely response is not received, the petition will be dismissed without consideration on the merits.
RESPONDING TO THIS INQUIRY LETTER ONLINE
You are encouraged to use the “Response to Petition to Director Inquiry Letter” online response form available at http://www.gov.uspto.report/trademarks/teas/response_forms.jsp (form number 11), but please wait 48-72 hours before responding if you received notification of the Inquiry Letter by e-mail. For technical assistance with the online form, please e-mail TEAS@uspto.gov.
Sincerely,
/Deborah D Mays/
Paralegal Specialist
Office of the Deputy Commissioner
for Trademark Examination Policy
(571) 272 9575